Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Delta Lloyd acquires 5.4% of Galapagos
Delta Lloyd Levensverzekeringen has disclosed that it holds 1.14 million shares in the share capital of Galapagos, as of September 1, 2008. This is the first notification Galapagos
Delta Lloyd Levensverzekeringen has disclosed that it holds 1.14 million shares in the share capital of Galapagos, as of September 1, 2008. This is the first notification Galapagos
Under the financing, Panacea Biotec’s subsidiary has agreed to purchase approximately 3.73 million shares of PharmAthene common stock at a negotiated price of $3.50 per share, which represents
Endovascular valve edge-to-edge repair (Everest) study is an FDA-approved Phase II randomized, controlled, multi-center clinical research study in the US and Canada evaluating the safety and efficacy of
The collaboration comprised the development and commercialization of new products based on botulium toxin and potential for Q-Med to distribute Medy-Tox’s existing botulinum toxin type A product. The
The main objective of the partnership is for Cellumen to develop a panel of Cellular Systems Biology (CSB) assays, as well as biosensors of key protein:protein interactions, that
Under the agreement, Advinus and Ortho-McNeil-Janssen Pharmaceuticals (OMJPI) have agreed to develop drug candidates for various disease targets. Advinus will be responsible for drug discovery and early clinical
The data generated will be used to better understand the unique benefit/risk characteristics of this important group of antimicrobial drugs, thereby helping to adapt and optimize future clinical
Agility will become part of GE Healthcare’s global diagnostic imaging services business, a provider of solutions enabling healthcare providers to achieve performance results through a combination of consulting
Prior to joining Seattle Genetics, Dr Waller was with Sonus Pharmaceuticals, where she served as senior vice president of regulatory affairs/quality assurance and clinical research until its merger
The Phase I study is expected to yield important information about the safety and immunogenicity of VaxInnate’s hemagglutinin (HA)-flagellin flu vaccine candidate. The study is taking place at